Companies › Geneos Therapeutics
2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GNOS-PV02 personalized neoantigen DNA vaccine | – | Phase 2 | HCC | Nov 2028 |
| INO-9012 plasmid encoded interleukin-12 (IL-12) vaccine adjuvant | IL12 | Phase 2 | HCC | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04251117 | GNOS-PV02 | Phase 1 | HCC | Oncology | Nov 2028 |
| NCT04251117 | INO-9012 | Phase 1 | HCC | Oncology | Nov 2028 |
| NCT07722741 | GNOS-PV02 | Phase 2 | HCC | Oncology | Sep 2029 |
| NCT07722741 | INO-9012 | Phase 2 | HCC | Oncology | Sep 2029 |
Strand Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix
Newish Technology (Beijing) BrainChild Bio TVAX Biomedical Lukas Biomedical RhoVac APS
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.